PODD · 10-Q · 2026Q3 · Full report
Revenue Performance and Mix
INSULET CORP · 2026-11-04 · Importance 59 · Surprise 48 · In source text
Total revenue for the nine months ended September 30, 2026 increased 25.0% to $2,405.4 million from $1,924.3 million, primarily on higher sales volume from customer-base growth. U.S. Omnipod revenue rose 20.6% to $1,630.1 million, while international Omnipod revenue increased 40.8% to $760.8 million, including a 4.4% favorable currency impact. In the three-month period, U.S. Omnipod revenue increased 14.7% to $570.4 million and international Omnipod revenue rose 31.7% to $266.2 million; international growth also reflected higher average selling prices from the Omnipod DASH-to-Omnipod 5 transition. Drug Delivery revenue declined 54.7% to $14.6 million in the nine-month period, driven by lower order volumes; U.S. Omnipod revenue in 2025 included $511.6 million of sales to a distributor considered a related party during part of that year.
Key facts
- Total revenue for the nine months ended September 30, 2026 was $2.4 billion, up $481.1 million or 25.0% from $1.9 billion in 2025. source
- U.S. Omnipod product revenue for the nine months ended September 30, 2026 was $1,630.1 million, up $278.1 million or 20.6% from $1,352.0 million in 2025. source
- Total revenue for the three months ended September 30, 2026 was $842.0 million, up $135.8 million or 19.2% from $706.3 million in 2025. source
- U.S. Omnipod product revenue for the three months ended September 30, 2026 was $570.4 million, up $73.3 million or 14.7% from $497.1 million in 2025. source
- Constant-currency revenue growth was 19.6% for the three months and 23.8% for the nine months ended September 30, 2026, primarily driven by higher sales volume from customer-base growth. source
- Insulet expects to generate an increasing portion of revenue through sales of disposable Pods as its customer base grows, providing a recurring revenue stream. source
- Insulet’s pay-as-you-go pricing model reduces upfront financial risk for third-party payors. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +57.1% | Total revenue for the nine months ended September 30, 2026 was $2.4 billion, up $481.1 million or 25.0% from $1.9 billion in 2025. |
| revenue | positive | realized | +16.1% | Total revenue for the three months ended September 30, 2026 was $842.0 million, up $135.8 million or 19.2% from $706.3 million in 2025. |
| revenue | positive | realized | +8.7% | U.S. Omnipod product revenue for the three months ended September 30, 2026 was $570.4 million, up $73.3 million or 14.7% from $497.1… |